FDA Policy for REMS Reqmts during COVID-19
Health Care, Pharma Industry, Strategic Planning
FDA is issuing this guidance to communicate its temporary policy for certain risk evaluation and mitigation strategies (REMS) requirements for the duration of the coronavirus pandemic public health emergency.
Read the Policy now
Related Education Resources.
All ResourcesLeadership Lessons for Re-Entry
Topics: Leadership, Management
Webinar
Free
Environmental Sustainability & the Supply of Medicines for Use in Clinical Trials
Topic: Supply Chain
White Paper
Free
Nat'l Coronavirus Response - Road Map to Reopening
Topics: Health Care, Strategic Planning
Report
Free
